Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Zura Bio Ltd (ZURA)

Zura Bio posts updated corporate presentation for investor meetings

Neutral Impact 2 of 5 other Written later

Zura Bio Limited furnished an updated corporate presentation dated August 17, 2026, for use at upcoming conferences and investor meetings, filed as Exhibit 99.1. The filing contains no financial results or guidance; the presentation covers the company's tibulizumab pipeline, including Phase 2 studies in hidradenitis suppurativa and systemic sclerosis, and states a cash runway through at least year end 2028.

Key points

  • Presentation dated August 17, 2026, filed as Exhibit 99.1 and posted at investors.zurabio.com
  • Topline data from the HS Phase 2 study expected in Q4 2026; the SSc Phase 2 study in H1 2027
  • Company states cash runway through at least year end 2028
  • No financial results or guidance included; information is furnished under Item 7.01 and not deemed filed

The filing

CompanyZura Bio Ltd (ZURA)
Form8-K, current report
Filed with the SECAug 17, 2026, 7:00 AM ET
Accession number0001104659-26-097526

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 17, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.